Home › Companies › KAPA

Kairos Pharma

Market cap $1.9M 4.7M shares (10-Q, Nov 13, 2026) × $0.400 close Nov 17, 2026

Most recent annual filing: 2026-03-31

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. ENV-105 lung Ph1 interim2026ENV-105 lung Ph1 interim, 2026, material
  2. Lonza manufacturing contract updateJan 2027Lonza manufacturing contract update, Jan 2027, routine
  3. KAPA stock listing updateJul 1, 2027KAPA stock listing update, Jul 1, 2027, routine
  4. NCT05534646 readout4Q 2027NCT05534646 readout, 4Q 2027, notable
  5. Enviro-Cedars license BLA filingJun 2028Enviro-Cedars license BLA filing, Jun 2028, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (12 active programs)

Discontinued (1)

Capital (as filed)

Cash
$3.1M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$979K quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$3.1M cash per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (3)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Kairos Pharma, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Avoid Kairos Pharma (KAPA) - Scientific Deep Dive for ENV-105 and Pipeline Products Recycled antibody with a 0-for-5 randomized record, zero objective responses in prostate cancer, a nine-patient efficacy story benchmarked against the wrong controls, and a balance sheet that cannot pay for already-ordered drug substance.
  2. Watch UPDATE: Kairos Pharma (KAPA) - The Control Arm Finally Shows Up The randomized control arm is now public with a striking 17.7 vs 2.0-month PFS gap, but missing arm sizes, hazard ratio, endpoint definition, and safety data prevent a higher conviction call; balance sheet remains stressed.
  3. Avoid UPDATE: Kairos Pharma (KAPA) - The Financing Front-Ran the Box Score Shares diluted 25.7% since the readout via ATM sales, the first post-readout filing adds no new data behind the 17.7 vs 2.0-month headline, a $0.25 no-cure delisting trigger arrives July 2027, and the capital structure risk now dominates the science.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (25)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 21, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

2 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)